News and Announcements
MD Anderson Leukaemia Expert Joins Prescient Therapeutics SAB
- Published November 27, 2015 3:34PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th November 2015, ASX Announcement
Cancer drug development company Prescient Therapeutics Ltd (ASX: PTX) is delighted to announce the appointment of an internationally regarded leukemia authority to its Scientific Advisory Board.
Professor Farhad Ravandi MD is based at the MD Anderson and Moffitt Cancer Center, which is one of the world’s most prestigious cancer institutions.
He currently holds position as Professor and Chief, Section of Developmental Therapeutics within the Department of Leukemia (AML) in early 2016.
Professor Ravandi is actively involved in clinical and translational research for the treatment of patients with various hematological malignancies, with a particular focus on leukemias.
To read the full announcement, please click here.